Abstract: The present invention provides a method for producing mesenchymal cells for production of mesenchymal cells for formation of a tooth, the method comprising: culturing totipotent stem cells in the presence of a differentiation inducer to produce a cell population after differentiation induction treatment, the cell population containing CD44-positive and CD29-positive cells or CD44-positive and CD106-positive cells; and selecting, from the cell population after the differentiation induction treatment, the CD44-positive and CD29-positive cells or CD44-positive and CD106-positive cells as the mesenchymal cells for the formation of the tooth.

Abstract: The ultrasonic-transducer mounting structure includes: a housing including: a body part which is formed into a hollow cylindrical shape and is provided at its front surface with a transmission surface allowing an ultrasonic wave to pass therethrough and is designed to accommodate an ultrasonic transducer therein; and plural connection pieces provided to a side surface of the body part; and a holder fixed to a rear surface of a bumper and designed to hold the housing such that the transmission surface of the housing is exposed via an opening of the bumper. The holder includes plural reception pieces to which the plural connection pieces are detachably coupled respectively. The plural reception pieces are fixed to the rear surface of the bumper to surround the opening.

Abstract: A main object of the present invention is to provide a novel pyridine derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, which may be substituted by an optionally substituted alkyl group, a hydroxy group, a halogen atom or a group represented by general formula [2]. In formula [2], -L1-L2-L3-RA ??[2] L1 and L3 independently represent a single bond, an alkylene group or a cycloalkylene group; L2 represents a single bond, O, or NRB; RB represents H or an optionally substituted alkyl group; and RA represents B, an amino group, a cyano group, a hydroxy group, an alkoxy group, an aryl group, a monoalkylamino group, a dialkylamino group, a carbamoyl group, an alkyloxycarbonyl group, a monoalkylaminocarbonyl group, a dialkylaminocarbonyl group, an alkylcarbonylamino group, and a saturated heterocyclic group, among other groups.

Abstract: The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.

Abstract: A first cell mass substantially containing only either one of mesenchymal cells or epithelial cells and a second cell mass substantially containing only the other one of the cells are positioned in contact with each other inside a support carrier which can maintain a condition of cell contact; and cultured to obtain a tooth having a specific cell placement. Preferably, after the culturing, the support carrier having both cell masses is cultured with kidney cells.

Abstract: The object of the present invention is to provide a method for restoring the alveolar bone of a mammal with a missing tooth. The present invention provides a method for restoring the alveolar bone in a mammal with a missing tooth comprising a step of transplanting a regenerated tooth unit to the said missing site. The regenerated tooth unit is characterized in that it has a periodontal tissue portion in addition to a tooth crown portion.

Abstract: Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.

Abstract: A method for manufacturing a regenerated tooth unit comprising a step of disposing and culturing a regenerated tooth germ inside a spacer in vivo in the body of a mammal is provided, wherein said spacer is configured so as to enable prevention of said regenerated tooth germ being extended to more than the maximum tolerance; and configured such that the regenerated tooth germ disposed inside is communicatable with the exterior of the spacer.

Abstract: An obstacle detection system includes ultrasonic sensors and a controller. The ultrasonic sensors include first and second ultrasonic sensors. Each of them is located at either side of a vehicle bumper so that its own beam axis has an angle deflected in a horizontal direction from a surface-normal direction of the bumper and is directed towards an intermediate portion of the bumper.

Abstract: A first cell mass substantially containing only either one of mesenchymal cells or epithelial cells and a second cell mass substantially containing only the other one of the cells are positioned in contact with each other inside a support carrier which can maintain a condition of cell contact; and cultured to obtain a tooth having a specific cell placement. Preferably, after the culturing, the support carrier having both cell masses is cultured with kidney cells.

Abstract: Disclosed are a perfusion culture method and a perfusion culture device whereby a perfusate can be delivered to all parts of an organ or tissue so that the organ or tissue can be preserved while sufficiently maintaining the function thereof. Specifically disclosed is a method for perfusion culture of an organ or tissue removed from a mammal, said organ or tissue having been removed together with a second organ or tissue connected to the aforesaid organ or tissue in vivo, which comprises a step for fixing said second organ or tissue so as to hang the aforesaid organ or tissue and a step for perfusing blood vessels in the aforesaid organ or tissue with a perfusate.

Abstract: Disclosed is a method for producing a tooth, which comprises the steps of: positioning a first cell mass substantially comprising either one of amniotic mesenchymal cells or epithelial cells, and a second cell mass substantially comprising the other one in the inside of a support carrier while keeping them in close contact with each other without being mixed together; and culturing the first and second cell masses in the inside of the support carrier.

Abstract: Disclosed is a glucagon-like peptide-1 (GLP-1) analogue which is obtained by ameliorating a highly antigenic GLP-1 analogue so that the GLP-1 analogue has reduced antigenicity without being lowered in the blood glucose suppressing activity. Specifically disclosed is a glycosylated form of an antigenic GLP-1 analogue, which has GLP-1 activity and is obtained by substituting at least one amino acid of an antigenic GLP-1 analogue with a glycosylated amino acid.

Abstract: Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.

Abstract: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R1: formula (1A): [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group ?: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.

Abstract: Specified phenylalanine derivatives and analogues thereof have an antagonistic activity to ?4 integrin. They are used as therapeutic agents for various diseases concerning ?4 integrin.

Abstract: Disclosed is a synthetic AILIM extracellular domain which has high ligand-binding ability and a quality sufficient for a pharmaceutical product. Also disclosed is a method for synthesizing the synthetic AILIM extracellular domain. Specifically disclosed is a sugar chaim-added AILIM extracellular domain wherein a sugar chain is bound at a position corresponding to the 69-position of the amino acid sequence of human AILIM extracellular domain, said amino acid sequence being depicted in SEQ ID NO: 7, and no sugar chain is added at positions corresponding to the 3-position and the 90-position of the amino acid sequence.

Abstract: Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.

Abstract: Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

Abstract: A method for producing a tooth having a desired length in one direction includes the steps of: placing a first cell aggregate and a second cell aggregate in the inside of a support while bringing the first and the second cell aggregates into close contact with each other; and culturing the first and the second cell aggregates in the inside of the support, in which the first cell aggregate is composed of one of mesenchymal cells or epithelial cells and the second cell aggregate is composed of the other, and the size of the tooth is controlled by adjusting the length of contact between the first cell aggregate and the second cell aggregate in one direction.